News

June 03, 2010

For nearly eighty years, UCSF researchers and clinicians have been making breakthrough discoveries that have improved diabetes treatment and care for individuals with diabetes and their families.

March 05, 2010

What better way to describe the clinical trial experience than through the eyes of a study participant?  In this month's Popular Science magazine, journalist Catherine Price writes about her experience in a new-onset type 1 diabetes clinical study involving the monoclonal antibody anti-CD3.

March 05, 2010

Since March is National Kidney Month and March 11, 2010 is officially World Kidney Day, we'd like to acknowledge the tremendous success of our UCSF Transplantation Program. UCSF has performed more kidney transplants than any other institution in the world — more than 8,300 since 1964 — and is the fifth largest center for living-donor kidney transplants in the country.

March 05, 2010

Bay area employers are concerned about the rising incidence of diabetes in today's society. One of three families are affected by diabetes or at risk for contracting this disease. Providing education on diabetes prevention, warning signs, common myths, and general treatment options is vitally important to keep staff healthy and happy.

March 05, 2010

At the 7th World Congress on Insulin Resistance, researchers from the UCSF Diabetes Center received awards for their new research involving insulin resistance.  Sinan Tanyolac, MD, a UCSF visiting scholar from Istanbul University who works closely with Diabetes Center researchers Ira Goldfine, MD and John Kane, MD , received first place for studies on the genetics of insulin resistance and type 2 diabetes.

March 05, 2010

It is hard to believe that a single patient can lead to new insights into autoimmune disease that merit publication in the New England Journal of Medicine (NEJM) . In a recent Letter to the Editor in the journal, our DC investigators report the case of a patient seen at the San Francisco General Hospital with symptoms of autoimmune polyglandular syndrome type 1 (APS1).

March 05, 2010

A recent study involving a previously unstudied gene known as Rfx6 has shown how this gene is necessary for cells to differentiate into insulin-producing beta cells and other cells in the pancreas. This study was led by Michael German, MD, Diabetes Center Clinical Director and the Justine K. Schreyer Endowed Chair in Diabetes Research, and his colleague Constantin Polychronakos, MD, of McGill University.

December 23, 2009

Forbes magazine’s annual feature on the Most Powerful People included UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, among the world’s seven Most Powerful Innovators. The story appearing in the November 30 issue called Desmond-Hellmann a “hero to legions of cancer patients” for her role in the development of the cancer drugs Avastin and Herceptin.

December 23, 2009

In conjunction with last month's National Diabetes Month, KPIX CBS 5 in San Francisco spotlighted the work of the Diabetes Center at UCSF.  On November 10th, CBS 5 Healthwatch Doctor Kim Mulvihill, MD discussed an experimental drug called anti-CD3 and how it may stop beta cell destruction in type 1 diabetes.

December 23, 2009

Three Diabetes Center affiliated researchers are featured in a recent issue of Forefront magazine, a publication of the American Diabetes Association (ADA).  Robert Farese Jr., MD, a senior scientist at the UCSF Gladstone Institute of Cardiovascular Disease, is studying the biology of fat storage. 

December 23, 2009

Within the last year, one of our type 1 diabetes clinical trials involving an effective cancer drug concluded.  Results published in November 2009 in the New England Journal of Medicine (NEJM)shows that anti-CD20 (FDA approved and marketed as Rituxan) has been shown to be effective in new onset diabetes by slowing down the progression of the disease.

December 23, 2009

It is hard to believe that we are just days away from the end of the decade, and nearly ten years since the founding of the UCSF Diabetes Center. I am grateful for the progress we continue to make toward preventing, treating and ultimately curing diabetes.  

November 17, 2009

Last month, the California Institute of Regenerative Medicine (CIRM) awarded a Diabetes Disease Team Award to Novocell, Inc., a San Diego-based stem cell engineering biotech, and the UCSF Diabetes Center, led by Jeffrey Bluestone, PhD, Michael German, MD, Matthias Hebrok, PhD, and Qizhi Tang, PhD.  Called the "dream team" by CIRM working group reviewers, this group's

Pages